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INTRODUCTION 
 Renal   cell carcinoma is the most   frequently occurring solid 
lesion within the kidney and comprises different RCC types with specific 
histopathological and genetic characteristics (1). There is a 1.5:1 
predominance of men over women, with peak incidence occurring 
between 60 and 70 years of age. Renal cell carcinoma   represents 2-3% 
of all cancers is the most lethal of the urologic cancers   
This is primarily a disease of the elderly patient, with typical 
presentation in the sixth and seventh decades of life ( Pantuck et al, 
2001).  The worldwide and European annual increase in incidence is 
approximately 2%,(3) with approximately 30,000 new cases expected per 
year in the U.S. and 20,000 cases expected in the European Union, with a 
relative increase of  30% in the past 2 decades.  Marked   international 
variation in incidence exists being high in Northern Europe and North 
America and low in Asia, Africa and South America [Waterhouse et al]. 
In India RCC incidence is 3 per 100000 in males and 2.1 per 
100000 in females per year.  The incidence rate approaches 200,000 per 
year worldwide. The incidence of RCC has increased since the 1970s  by 
an average of 3% per year for whites and 4% per year for African 
Americans, largely related to the more  prevalent use of  ultrasonography 
and CT scan for the evaluation of a variety of abdominal or 
gastrointestinal complaints ( Chow et al, 1999 ). 
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  Surgical resection of the involved kidney is by far the most 
successful intervention for localized RCC, yet at diagnosis, nearly 30% of 
patients present with metastatic disease. Despite intense surgical efforts, 
30% to 40% of patients with no evidence of metastasis at time of surgery 
will subsequently develop distant metastasis.   Eventually, 50% to 60% of 
all RCC patients develop metastatic disease. The 5-year survival rate for 
RCC patients with stage IV metastatic disease is a dismal 10%. Current 
methods for surveillance of disease progression after surgery are based 
entirely on clinical and Pathologic indices and do not incorporate 
molecular markers from tumor tissues.    
   Important predictors of outcome for RCC include tumor stage, 
Fuhrman nuclear grade, histopathological classification and   peri 
operative thrombocytosis.  Patient performance status using the ECOG 
classification system has been independently linked to outcome in 
patients with RCC, and figures prominently in the UISS nomogram from 
UCLA. The presence of local or systemic tumor symptoms have also 
been shown to be an independent predictor of patient outcome.  There is 
no single prognostic variable which determines the recurrence. So we 
have done this study to find out if microvascular invasion can be 
considered as the most important prognostic variable predicting 
recurrence. 
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AIM OF THE STUDY 
 To evaluate the importance of various prognostic factors which 
determine the recurrence in RCC following radical nephrectomy and find 
out if microvascular invasion in tumors can turn out to be the most 
important prognostic variable of all the established prognostic variables. 
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REVIEW OF LITERATURE 
The wide spread use of imaging in current medical practice has 
lead to an increased diagnosis of incidental renal tumors. However the 
incidentalomas represent 50% of RCCs diagnosed. And 20-40% develop 
metastases after nephrectomy for localized disease. Etiological factors 
include lifestyle factors, such as smoking, obesity and antihypertensive 
therapy (4, 5, 6).  Cigarette smoking is a definite risk factor for RCC.    
The roles of obesity and prolonged intake of antihypertensive 
medication as risk factors for RCC remain to be definitively clarified (7). 
The most effective prophylaxis is to avoid cigarette smoking. The most 
important primary prevention for RCC is to eliminate cigarette smoking 
and to avoid obesity (8, 9, 10). Although a number of potential etiologic 
factors have been identified in animal models, including viruses, lead 
compounds, and more than 100 chemicals such as aromatic 
hydrocarbons, no specific agent has been definitively established as 
causative in human RCC (Kantor, 1977). The majority of cases of RCC 
are believed to be sporadic; the National Cancer Institute estimates that 
only 4% are familial. Von Hippel–Lindau, Hereditary papillary RCC, 
Familial leiomyomatosis and RCC, Birt-Hogg-Dube syndrome. 
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PATHOLOGY 
Most RCCs are round to ovoid and circumscribed by a 
pseudocapsule of compressed parenchyma and fibrous tissue rather than a 
true histologic capsule. Unlike upper tract transitional cell carcinomas, 
most RCCs are not grossly infiltrative, with the notable exception of 
collecting duct RCC and some sarcomatoid variant (Farrow, 1997). 
Tumor size has ranged from 5 to 8 cm in most series but can vary from a 
few millimeters to large enough to fill the entire abdomen.  . When they 
are bivalved, RCCs consist of yellow, tan, or brown tumor interspersed 
with fibrotic, necrotic, or hemorrhagic areas; few are uniform in gross 
appearance.  
 Cystic degeneration is found in 10% to 25% of RCCs and appears 
to be associated with a better prognosis compared with purely solid RCC 
(Imura et al, 2004 ). Calcification can be stippled or plaque like and is 
found in 10% to 20% of RCCs. Nuclear features can be highly variable, 
and a number of grading systems have been based on such features as 
nuclear size and shape and the presence or absence of prominent 
nucleoli(11,18). Fuhrman's system has been most generally adopted and 
is now recognized as an important independent prognostic factor for 
(Fuhrman et al, 1982).  Frank invasion and perforation of the collecting 
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system or renal capsule are found in approximately 20% of cases, 
although displacement of these structures is a more common finding. 
Further spread to involve adjacent organs is often precluded by Gerota's 
fascia acting as a barrier.   One unique feature of RCC is its predilection 
for involvement of the venous system, which is found in 10% of RCCs, 
more often than in any other tumor type This is most commonly 
manifested in the form of a contiguous tumor thrombus that can extend 
into the inferior vena cava as high as the right atrium. Many such tumor   
thrombi are highly vascularised by arterial blood flow  (Novick et al, 
1990).  Most sporadic RCCs are unilateral and unifocal. Bilateral 
involvement can be synchronous or asynchronous and is found in 2% to 
4% of sporadic RCCs, although it is considerably more common in 
patients with Von Hippel–Lindau disease or other familial forms of RCC 
(Linehan et al, 2003).  Multicentricity, which is found in 10% to 20% of 
cases, is more common in association with papillary histology and 
familial RCC.  
Satellite lesions are often small and difficult to identify by 
preoperative imaging, intraoperative ultrasonography, or visual 
inspection; they appear to be the main factor contributing to local 
recurrence after partial nephrectomy. All RCCs are, by definition, 
adenocarcinomas, derived from renal tubular epithelial cells Most RCCs 
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share ultrastructural features, such as surface microvilli and complex 
intracellular junctions, with normal proximal tubular cells, and they are 
believed to be derived from this region of the nephron (11, 12). But it is 
not the case in other pathological types of RCCs which are believed to 
arise from other parts of nephron. Conventional RCC accounts for 
approximately 70% to 80% of all RCCs, representing the garden variety 
of RCC ( Störkel et al, 1997 ). These tumors are typically yellow when 
they are bivalved and are highly vascular, containing a network of 
delicate vascular sinusoids interspersed between sheets or acini of tumor.  
On microscopic examination, common or conventional RCC can include 
clear cell, granular cell, or mixed types. Clear cells are typically round or 
polygonal with abundant cytoplasm containing glycogen, cholesterol, 
cholesterol esters, and phospholipids, all of which are readily extracted by 
the solvents used in routine histologic preparations, contributing to the 
clear appearance of the tumor cells (Farrow, 1997). However, granular 
cells, which have eosinophilic cytoplasm and abundant mitochondria, can 
predominate. Two percent to 5% of conventional RCCs also demonstrate 
sarcomatoid features, and conventional RCC is more likely to exhibit 
venous tumor extension than is any other subtype of RCC (Rabbani et al, 
2004).  
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In general, patients with conventional RCC have a worse prognosis 
compared with chromophilic or chromophobic RCC, even after 
stratification for stage and grade (Cheville et al, 2003; Beck et al, 2004). 
However, most responders in immunotherapy protocols have had 
conventional RCC, and these protocols are now being reserved primarily 
for this population (Childs et al 2000; Drachenberg and Childs, 2003). 
Chromosome 3 alterations and VHL mutations are common in 
conventional RCC, and mutation or inactivation of this gene has been 
found in a majority of sporadic cases ( Linehan et al, 2003).  
Chromophilic RCC, which has also been designated papillary RCC in 
other classification schemes, is the second most common histologic 
subtype (Störkel et al, 1997). It represents 10% to 15% of all RCCs, 
although it is more commonly found in certain populations, such as 
patients with end-stage renal failure and acquired renal cystic disease  
(Störkel et al, 1997). On microscopic examination, most tumors in this 
category consist of basophilic or eosinophilic cells arranged in papillary 
or tubular configuration. The cytogenetic abnormalities associated with 
chromophilic RCC are characteristic and include trisomy of 
chromosomes 7 and 17 and loss of the Y chromosome (13, 14,)       
Another unique feature of chromophilic RCC is its tendency 
toward multicentricity, which approaches 40% in many series (Chow et 
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al, 2001).At present, many authors believe that grade for grade and stage 
for stage, a significant difference in outcome for patients with 
chromophilic RCC versus conventional RCC may be difficult to 
demonstrate (Renshaw, 2002). Chromophobe cell carcinoma is a 
distinctive histologic subtype of RCC that appears to be derived from the 
cortical portion of the collecting duct (Störkel et al, 1997). It represents 
3% to 5% of all RCCs (Oyasu, 1998). The tumor cells typically exhibit a 
relatively transparent cytoplasm with a fine reticular pattern that has been 
described as a “plant cell” appearance. A perinuclear halo is typically 
found, and electron microscopic findings consist of numerous 150- to 
300-nm microvesicles, which are the single most distinctive and defining 
feature of chromophobe cell carcinoma (Krishnan and Truong, 2002).  
Collecting duct or Bellini's duct, carcinoma is a relatively rare subtype of 
RCC, accounting for less than 1% of all RCCs. Many reported cases have 
occurred in younger patients, often in the third, fourth, or fifth decade of 
life (Carter et al, 1992).  Collecting duct carcinomas are derived from the 
medulla, but many are infiltrative, and extension into the cortex is 
common (Pickhardt et al, 2001). 
 On microscopic examination, these tumors consist of an admixture 
of dilated tubules and papillary structures typically lined by a single layer 
of cuboidal cells, often creating a cobblestone appearance. Renal 
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medullary carcinoma is a relatively new subtype of RCC that occurs 
almost exclusively in association with the sickle cell trait. It is typically 
diagnosed in young African Americans, often in the third decade of life 
(Swartz et al, 2002). Renal medullary carcinoma is thought to arise from 
the calyceal epithelium near the renal papillae but is often highly 
infiltrative   (Davis et al, 1995). Many cases are both locally advanced 
and metastatic at the time of diagnosis. Most patients do not respond to 
therapy and succumb to their disease in a few to several months (Polascik 
et al, 2002). The site of origin (renal papillae) and association with sickle 
cell trait suggest that a relatively hypoxic environment may contribute to 
tumorigenesis.  
DIAGNOSIS AND STAGING 
Due to the increased detection of tumours by the use of imaging 
techniques such as ultrasound and Computerized tomography (CT), an 
increasing number of incidentally diagnosed RCCs are found. These 
tumours are more often smaller and of low stage (8-10).   Despite the 
increased incidental detection rate, the mortality from RCC has remained 
unaffected and parallel to the incidence. Many renal masses remain 
asymptomatic and non- palpable until late in the natural course of the 
disease today, more than 50% of RCCs are detected incidentally using 
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non-invasive imaging for the evaluation of a variety of non-specific 
symptom complexes (17, 19). 
The classic triad of flank pain, gross haematuria and palpable 
abdominal mass is now rarely found in (6-10%).  Paraneoplastic 
syndromes are found in around 30% of patients with symptomatic RCC 
(21, 23). The most common of these are, hypertension, cachexia, weight 
loss, pyrexia, neuromyopathy, amyloidosis, elevated erythrocyte 
sedimentation rate, anaemia, abnormal liver function,  hypercalcaemia,  
polycythaemia, etc, (20-22). 
   A minority of patients present with symptoms directly caused by 
metastatic disease, such as bone pain or persistent cough (1). Still, 25-
30% of patients are diagnosed due to symptoms      associated with    
metastatic disease. Physical examination has a limited role in diagnosing 
RCC, but it may be valuable in some cases such as palpable abdominal 
mass, palpable cervical lymphadenopathy, non-reducing varicocele or 
bilateral lower extremity oedema, which suggests venous involvement. 
These findings should initiate radiological examinations. The most 
commonly assessed laboratory parameters are haemoglobin, erythrocyte 
sedimentation rate, alkaline phosphatase and serum calcium (1, 4) .The 
staging system used is 2002 TNM system which gives idea about the 
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local, regional and systemic extent of tumor pre operatively. Tumors 
which are enhancing on contrast administration are taken as malignant 
and there is no role of pre operative biopsy as there is false negative rate 
of around 30% by conventional HPE methods.  Since there is difficulty  
in differentiating benign and malignant neoplasm there is a role of 
fluorescent in situ hybridization  (FISH) technique  which has a  
sensitivity and specificity of more than 95% because it looks for the 
specific chromosomal abnormalities present in individual tumors.The 
local staging is assessed by seeing the size of the tumor and how the fat 
plane between the tumor and surrounding structures is maintained. 
Typical  perinephric stranding is looked for which is due to the 
obstruction of  lymphatics by the tumor cells. The presence of hilar, 
caval, inter aorto caval and para aortic nodes are looked for. The signs of 
venous involvement are looked for by seeing at the shape of IVC and any 
filling defect. The presence of metastasis is assessed by evaluating 
according to symptoms. 
RADIOLOGICAL INVESTIGATIONS 
The majority of renal tumours are diagnosed by abdominal 
ultrasound (US) and CT performed for various reasons (24, 25).  
Detection of a solid renal mass with US should be further investigated 
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with a high-quality CT scan using contrast medium (26, 32). It serves to 
verify the diagnosis of RCC and provides information on the function and   
morphology of the contralateral kidney.  
  Abdominal CT assesses primary tumour extension with extrarenal 
spread and provides information on venous involvement, enlargement of   
locoregional lymph nodes, and condition of adrenal glands and the liver 
(27, 29). Chest CT is the most accurate investigation for chest staging 
(28), but at least routine chest radiography, as a less accurate alternative, 
must be done for metastatic evaluation. A plain chest X-ray can be 
sufficient for assessment of the lung in low-risk patients but chest CT is 
most sensitive (30, 31).  
Magnetic resonance imaging (MRI) can be reserved primarily for 
patients with locally advanced malignancy, possible venous involvement, 
renal insufficiency or allergy to intravenous contrast (34-35). Magnetic 
resonance imaging is also an option for the evaluation of inferior vena 
cava tumour thrombus extension and the evaluation of unclassified renal 
masses (36-38).  
Evaluation of the tumour thrombus can also be performed with 
Doppler US in such cases.  There is consensus that most bone and brain 
metastases are symptomatic  
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At the time of diagnosis and that routine bone scan or brain CT are 
not generally indicated (40).  In high-risk patients for bone metastases 
(raised alkaline phosphatase or bone pain), further evaluation utilizing an 
imaging approach should be done (39), if indicated by clinical or 
laboratory signs and symptoms, 
  Other diagnostic procedures may be applied, such as bone scan 
(41), brain CT or MRI. Renal   arteriography, inferior venacavography or 
fine-needle biopsy.   Have only a limited role in the clinical work-up of 
patients with RCC, but may be considered in selected cases. 
Routine evaluation by doing all the available modalities   is not 
necessary because it adds to the cost and does not help in the 
management. By CT if typical >20 HU enhancement  is made out and 
there is tumor deenhancement which is characteristic of RCC which is 
due to the lack of functioning tubules and increased  neo vascularity due 
to VEGF production especially in clear cell RCC  it virtually confirms the 
diagnosis . 
In certain situations when there is a central hilar tumor it is difficult 
to differentiate from collecting system tumors. In these cases we have to 
look for distortion of renal out line due to exophytic growth of tumor and 
neo vascularity which is due to increased growth factors. Usually   
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collecting system tumors are infiltative in nature and they don’t produce a 
palpable mass. They are also less vascular than   RCC due to absence of 
VEGF production. 
PROGNOSTIC FACTORS 
The 2002 TNM stage classification system is generally 
recommended for clinical and scientific use.  It is unclear whether the 
current TNM classification is optimal for the prediction of survival in 
patients with RCC and might be a subject for re-classification. The pT1 
substratification, introduced in 2002 (1), has been validated by a number 
of studies (2-4) However, refinements remain to be performed for pT3 
tumours 
 Firstly, for renal sinus fat invasion only,it has not been established 
whether this carries the same prognostic information as does perinephric 
fat invasion .  Secondly, many studies have suggested that adrenal 
invasion represents a very poor prognosticgroup.It has been suggested 
that these RCCs should be classified as T4 tumours . Furthermore, it is 
still not clearwhether the stratification of RCCs with venous invasion in 
T3b and T3c is accurate. Additional studies arerequired to investigate the 
independent prognostic value of vena caval invasion compared with renal 
vein invasion. More recently, the accuracy of the N1-N2subclassification 
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has been questioned.  For adequate M-staging of patients with RCC, an 
accurate pre-operative imaging procedure, which is currently chest and 
abdominal CT, should be performed. Factors influencing prognosis can 
be classified into: anatomical, histological, clinical and molecular. 
Anatomical factors 
Anatomical factors include tumour size, venous invasion, renal 
capsule invasion, adrenal involvement, and lymph node and distant 
metastasis. Overall, tumor-related factors such as pathologic stage, tumor 
size, nuclear grade, and histologic subtype have the greatest utility on an 
independent basis. However, an integrative approach, combining a 
variety of factors that have proved to have independent value on 
multivariate analysis, appears to be most powerful. ( Kontak and 
Campbell, 2003 ).  
Giuliani and colleagues (1990) reported 5-year survival rates of 
84% for patients with tumor diameter less than 5 cm, 50% for tumors 
between 5 and 10 cm, and 0% for tumors more than 10 cm in diameter. 
To a large extent, this is due to a strong correlation between tumor size 
and pathologic tumor stage. Guinan and coworkers (1995b) have also 
shown that tumor size can function as an independent prognostic factor.   
 22
 Frank and colleagues (2003a) have shown that larger tumors are 
more likely to exhibit clear cell histology and high nuclear grade, and 
both of these factors correlate with a compromised prognosis. A review 
of 1771 patients with organ-confined RCC showed 10-year cancer-
specific survival rates of 90% to 95%, 80% to 85%, and 75% for patients 
with pT1a,  pT1b, and pT2 tumor, respectively (Patard et al, 2004a). 
Other studies have also shown a particularly favorable prognosis for the 
unilateral pT1a tumors that are now being discovered with increased 
frequency. In series from the Cleveland Clinic and the Mayo Clinic, such 
tumors were associated with greater than 95% 5-year survival rates, 
whether they were managed by nephron-sparing surgery or radical 
nephrectomy( Cheville et al). 
Histological factors 
Pathologic stage has proved to be the single most important 
prognostic factor for RCC (Kontak and Campbell, 2003). The extent of 
loco-regional or systemic disease at diagnosis is the primary determinant 
of outcome for this disease ( Bassil et al, 1985 ). These studies 
demonstrate 5-year survival rates of 70% to 90% for organ-confined 
disease and document a 15% to 20% reduction in survival associated with 
invasion of the perinephric fat (Leibovich et al, 2005). Renal sinus 
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involvement should definitely be classified as T3a, and studies suggest 
that these patients may be at higher risk for metastasis related to increased 
access to the venous system (Bonsib et al, 2000; Uzzo et al, 2002).  
Several reports have shown that most patients with ipsilateral 
adrenal involvement, which is found in 1% to 2% of cases, eventually 
succumb to systemic disease progression, suggesting a hematogenous 
route of dissemination or a highly invasive phenotype (von Knobloch et 
al, 2004; Siemer et al, 2005; Thompson et al, 2005).   Venous 
involvement was once thought to be a poor prognostic finding for RCC, 
but several reports demonstrate that many patients with tumor thrombi 
can be salvaged with an aggressive surgical approach. These studies 
document 45% to 69% 5-year survival rates for patients with venous 
tumor thrombi as long as the tumor is otherwise confined to the kidney.  
Golimbu and associates (1986) reported 84% 5-year survival in the best 
of circumstances—tumor thrombus limited to the main renal vein and 
tumor otherwise confined to the kidney.  
Patients with venous tumor thrombi and concomitant lymph node 
or systemic metastases have markedly decreased survival, and those with 
tumor extending into the perinephric fat have intermediate survival 
(Gettman et al, 1999 ; Naitoh et al, 1999 ; Bissada et al, 2003 ; 
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Moinzadeh and Libertino, 2004 ;). The importance of tumor invasion into 
the perinephric fat and its negative impact on prognosis for patients with 
tumor thrombi is highlighted in the series by Leibovich. The prognostic 
significance of the cephalad extent of tumor thrombus has been 
controversial, and it is difficult to compare various series because of 
differences in selection of patients and related covariables ( Leibovich et 
al, 2005 ).  
However,   data suggest that the cephalad extent of tumor thrombus 
is not of prognostic significance as long as the tumor is otherwise 
confined  Direct invasion of the wall of the vein appears to be a more 
important prognostic factor than cephalad extent of tumor thrombus and 
should be noted during tumor staging. Hatcher and colleagues (1991) 
reported 69% 5-year survival when the wall of the vein was clean, which 
was reduced to 25% when direct invasion of the caval wall was observed.   
   Eastern Cooperative Oncology Group performance status, 
metastatic status, sarcomatoid features and concomitant perinephric fat 
invasion are the most powerful prognostic factors of survival in renal cell 
carcinoma with tumor thrombus extension. (Klatte et al) .The major drop 
in prognosis comes in patients whose tumor extends beyond Gerota's 
fascia to involve contiguous organs, which is rarely associated with 5-
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year survival, and in patients with lymph node or systemic metastases 
(Thrasher and Paulson, 1993).   
 Lymph node involvement has long been recognized as a dire 
prognostic sign because it is associated with 5- and 10-year survival rates 
of 5% to 30% and 0% to 5%, respectively ( Bassil et al, 1985 ; Phillips 
and Taneja, 2004 ). Median survival at follow up was 49 months. Five-
year cancer specific survival was 60% for pT3a, 46.2% for pT3b, 10% for 
pT3c and 12% for pT4 tumours (p <0.0001).  
According to median survival, the authors identified 3 prognostic 
groups, including GROUP 1-patients with renal vein thrombosis (117 
months), fat invasion (98 months) or infradiaphragmatic vena caval 
thrombosis (67 months), GROUP 2-patients with adrenal invasion alone 
(24 months), renal vein thrombosis plus fat invasion (24 months) or 
infradiaphragmatic vena cava plus fat invasion (24 months) GROUP 3-
patients with renal or infradiaphragmatic caval thrombosis plus adrenal 
involvement (11 months), supradiaphragmatic vena caval thrombosis (12 
months) or Gerota's fascia invasion (12 months). 
Five-year cancer specific survival rates in groups 1 to 3 were 61%, 
35% and 12.9%, respectively (p <0.0001). On multivariate analysis the 
proposed classification had an independent prognostic value.  Ficarra et 
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al. (2007) provide an adequate prognostic stratification for locally        
advanced renal cell carcinoma and propose a new TNM classification 
concluded that the results suggest the necessity of reclassifying locally 
advanced renal cell carcinoma according to the 3 described prognostic 
categories. 
 Systemic metastases portend a particularly poor prognosis for 
RCC, with 1-year survival of less than 50%, 5-year survival of 5% to 
30%, and 10-year survival of 0% to 5% (Negrier et al, 2002; Sella et al, 
2003). The statistics for patients presenting with synchronous metastases 
are even worse, with most patients dying of disease progression within a 
year. For patients with asynchronous metastases, the metastasis-free 
interval has proved to be a useful prognosticator becauseit reflects the 
tempo of disease progression ( Negrier et al, 2002 ).  
Other important prognostic factors for patients with systemic 
metastases include performance status, number and sites of metastases, 
anemia, hypercalcemia, elevated alkaline phosphatase or lactate 
dehydrogenase levels, and sarcomatoid histology (Motzer et al,2004). 
Visceral metastases have been associated with a particularly poor 
prognosis, in contrast to pulmonary-only disease,   ( Negrier et al, 2002 ).  
Bulky retroperitoneal lymphadenopathis now also established as a strong 
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negative prognostic factor in patients with metastaticRCC  
(Vasselli et al, 2001; Pantuck et al, 2003a,). Prior nephrectomy has 
correlated with improved survival and cytoreductive nephrectomy may 
provide a modest survival benefit, although the mechanism for this is 
under debate ( Flanigan et al, 2001 ).  
  Multivariate analysis identified the following independent adverse 
prognostic factors(PF)for progression free survival in advanced RCC  
(1)  time from diagnosis to current treatment < 2 years  
(2)  baseline platelet count > 300,000 cells/microliter (mcL)  
(3)  baseline neutrophil count > 4500 cells/mcL 
(4)  baseline corrected serum calcium < 8.5 or > 10.0 mg/dL; and 
(5)  initial ECOG performance status (PS) > 0.  
 
Using these factors, 3 prognostic subgroups were identified based 
on the number of adverse PFs presents. Median PFS in patients with 0 or 
1 adverse PFs was 20.1 months (95% CI, 19.0-22.3) compared with 13 
months (95% CI, 8.6-17.6) in patients with 2 adverse PFs and 3.9 months 
(95% CI, 1.8-7.2) in patients with more than 2 adverse PFs. A nomogram 
was created to estimate the likelihood of PFS of 12 or more months with 
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corrected calcium, PS, nephrectomy, lactate dehydrogenase, 
thrombocytosis, number of metastatic sites, and time from diagnosis to 
treatment.   
Other important prognostic factors for RCC   include nuclear grade 
and histologic subtype. Renal tumor classification is important because 
histopathological subtypes are associated with distinct clinical behavior. 
However, diagnosis is difficult because tumor subtypes have overlapping 
microscopic characteristics. Clear cell RCC overexpressed proximal 
nephron, angiogenic, and immune response genes, chromophobe RCC 
oncocytoma overexpressed distal nephron and oxidative phosphorylation 
genes, papillary RCC overexpressed serine protease inhibitors, and 
extracellular matrix products, and angiomyolipoma overexpressed muscle 
developmental, lipid biosynthetic, melanocytic, and distinct angiogenic 
factors.  
Quantitative reverse transcriptase-polymerase chain reaction and 
immunohistochemistry of formalin-fixed renal tumors confirmed 
overexpression of proximal nephron markers (megalin/low-density 
lipoprotein-related protein 2, α-methylacyl CoA racemase) in clear cell 
and papillary RCC and distal nephron markers (β-defensin 1, claudin 7) 
in chromophobe RCC/oncocytoma.  
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Histopathological subtypes of renal neoplasms expressed distinct, 
biologically relevant molecular signatures. For example, clear cell RCC 
was revealed as an immunogenic and angiogenic tumor related to 
proximal nephron epithelium. Chromophobe RCC and oncocytoma 
appeared to be closely related neoplasms, overexpressing distal nephron 
markers and energy pathway genes, and underexpressing IκB 
kinase/nuclear factor-κB regulators and cell death genes. Papillary RCC 
expressed a distinct molecular signature, including serine protease 
inhibitors, extracellular matrix products, and proximal nephron markers 
such as AMACR. Angiomyolipoma was characterized as a mesenchymal 
tumor with adipose, smooth muscle, vascular, and melanocytic features. 
Several grading systems for RCC have been proposed on the basis 
of nuclear size and morphology and presence or absence of nucleoli. 
Nuclear grade has proved in many cases to be an independent prognostic 
factor when it is subjected to multivariate analysis ( Patard etal ).    
In North America, Fuhrman's classification system has been most 
generally adopted. In Fuhrman's original report, the 5-year survival rates 
for grades 1 to 4 were 64%, 34%, 31%, and 10%, respectively, and 
nuclear grade proved to be the most significant prognostic factor for stage 
I tumors in this series ( Fuhrman et al, 1982 ).   In most series, prognostic 
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significance has been found primarily at the ends of the spectrum   given 
the   difficulties of distinguishing the intermediate grades; a consensus 
conference on tumor grading for RCC recommended changing to a three-
tiered system.  
             Histologic subtype can also carry prognostic significance, 
although, again, primarily at the ends of the spectrum. The presence of 
sarcomatoid differentiation or collecting duct or medullary cell histologic 
subtype denotes a poor prognosis    (Polascik et al, 2002).   
  Estimates of DNA ploidy and assessment of nuclear morphometry 
have also correlated with outcomes for patients with RCC, but the main 
utility of ploidy appears to be inpatients with organ-confined disease, and 
the role of nuclear morphometry has not   been defined. 
Clinical factors 
Clinical factors include patient performance status, localized 
symptoms, cachexia, anaemia, platelet count. Anemia, thrombocytosis, 
hypercalcemia, albuminuria, elevated serum alkaline phosphatase, 
erythrocyte sedimentation rate, and other paraneoplastic signs or 
symptoms have also correlated with poor outcomes for patients with RCC 
( Symbas et al, 2000 ).       
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In the large population study led by Verhoest and colleagues from 
several European hospitals, the clinical parameters for four patient age 
groups were evaluated to determine the influence of age at diagnosis on 
tumor characteristics and outcomes for RCC.  The authors concluded that 
age is indeed an independent prognostic variable for RCC clinical 
parameters and overall survival. Younger patients appear to have lower 
stage and grade tumors, and a higher incidence of more favorable 
histologic subtypes such as papillary and chromophobe.  Age at diagnosis 
should be considered in counseling patients regarding outcomes, but this 
factor should await further prospective validation prior to widespread 
implementation in prognostic nomograms,  because  although there are 
some studies to show  the younger age patients have  papillary histology 
and good prognosis when compared to older individuals no concrete 
evidence is available in the  studies available. 
Molecular factors 
There are numerous molecular markers being investigated 
including: carbonic anhydrase IX (CAIX), vascular endothelial growth 
factor (VEGF), hypoxia inducible factor (HIF), Ki67 (proliferation), p53, 
PTEN (cell cycle), Ecadherin, CD44 (cell adhesion) (55). As yet, these 
markers are not in wide spread use. Recently, gene expression profiling 
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has identified 259 genes, which predict survival independent of 
clinicalprognostic factors in conventional RCCs, indicating that genetic 
information will improve prognostication.  
The most promising of molecular factor appears to be CA-9, which 
is regulated by the VHL gene and is over expressed in many conventional 
RCCs (Bui et al, 2003, 2004 ). High CA-9 expression has correlated with 
improved survival in this population, suggesting that tumors with VHL-
independent pathogenesis may have increased aggressiveness.   
Decreased proliferative index as assessed by Ki-67 has also correlated 
with improved survival in clear cell RCC ( Bui et al, 2004 ). 
Other factors that may prove to be useful include apoptotic indices;   
genetic elements, such as p53 ( Shvarts et al, 2005 ); and evaluation of the 
expression and function of various growth factors and their receptors. 
Histopathological subtypes of renal neoplasms expressed distinct, 
biologically relevant molecular signatures. For example, clear cell RCC 
was revealed as an immunogenic and angiogenic tumor related to 
proximal nephron epithelium. Chromophobe RCC and oncocytoma 
appeared to be closely related neoplasms, overexpressing distal nephron 
markers and energy pathway genes, and underexpressing IκB 
kinase/nuclear factor-κB regulators and cell death genes. Papillary RCC 
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expressed a distinct molecular signature, including serine protease 
inhibitors, extracellular matrix products, and proximal nephron markers 
such as AMACR. Angiomyolipoma was characterized as a mesenchymal 
tumor with adipose, smooth muscle, vascular, and melanocytic features. 
Additional clinical or pathological properties may be revealed by further 
analysis of the microarray data and the case cohort. Consistent with 
various research results, microarray data could be translated into specific 
quantitative RT-PCR and immunohistochemical assays using formalin-
fixed paraffin-embedded tissues, which may be applicable in clinical 
settings for diagnosis and clinical management of renal tumors.    
Assays for the levels of proangiogenic factors such as VEGF or 
basic fibroblast growth factor in the serum or urine may also improve 
prognostication (Mizutani et al, 2003). Gene array and proteomic 
technology   identify additional prognostic factors ( Kim et al ) .  The 
active form of vitamin D3, that is 1alpha, 25-dihydroxyvitamin D3, binds 
with vitamin D receptor, which forms a complex with retinoid X 
receptors alpha, beta and gamma to manifest antitumor effects. Obara et 
al. (2007) examined the expression of vitamin D receptor and retinoid X 
receptors in renal cell carcinoma and elucidated the prognostic 
significance of these receptors.  They examined immunohistochemically 
vitamin D receptor, and retinoid X receptors alpha, beta and gamma in 
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nephrectomized specimens of 68 patients with renal cell carcinoma.They 
analyzed the correlation between the expression of these receptors and 
clinicopathological parameters or patient survival. The 5-year cancer 
specific survival rate was higher in patients with retinoid X receptor 
gamma positive renal cell carcinoma than those with retinoid X receptor 
gamma negative renal cell carcinoma (79.3% vs 40.0%, p < 0.05). 
Significant correlation was observed between the expression of retinoid X 
receptor gamma and tumor stage, distant metastasis or the 5-year cancer 
specific survival rate. 
 Furthermore, retinoid X receptor gamma expression was an 
independent prognostic factor in patients with renal cell carcinoma. The 
importance of molecular factors is now slowly getting established and 
there many studies to prove their significance in recurrence. The 
importance of various molecular factors in influencing the recurrence is 
not specifically known so that it can be utilized in prognostic nomograms.  
At present there are no nomograms using this factors in predicting the 
recurrence but in future these factors will come to play in selecting the 
follow up protocol and in selecting the adjuvant  therapy protocols. These 
need sophisticated methods of analysis but will be useful in predicting the 
biological behaviour of the tumor. 
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TREATMENT OF LOCALIZED DISEASE 
         Radical nephrectomy that includes the removal of the  tumour-
bearing kidney remains the gold standard curative therapy for patients 
with localized RCC and offers a reasonable chance of curing the disease 
(1).There is no evidence to favour a specific surgical approach.  Except in 
the case of a large upper pole tumour, which is associated with a risk of 
direct invasion of the adrenal gland, or a tumour of > 7 cm maximum 
diameter, which is associated with a higher risk of intra-adrenal 
metastatic spread, there is evidence that a routine adrenalectomy is 
unnecessary during the surgical treatment of RCC, provided the pre-
operative imaging procedures for tumour staging (CT, MRI) reveal 
negative findings. 
Current evidence that adjuvant tumour vaccination might improve 
the duration of the progression-free survival of selected subgroups of 
patients undergoing nephrectomy for T3 renal carcinomas needs further 
confirmation regarding the impact on overall survival.  Prognostic 
algorithms might identify patients likely to derive the largest clinical 
benefit from adjuvant vaccination therapy.  
         Adjuvant therapy with cytokines does not improve survival after 
nephrectomy Outside controlled clinical trials, there is no indication for 
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adjuvant therapy following surgery. There lot of molecular targeted 
therapies against tyrosine kinase, VEGF and other pathways which have 
some value in tumors with high chance of recurrence. 
SURVEILLANCE   FOLLOWING   SURGERY 
  Surveillance after radical surgery allows the urologist to   monitor 
or identify: 
• Post-operative complications 
• Renal function 
• Local recurrence 
• Recurrence in the contralateral kidney 
• Development of metastases. 
PROGNOSTIC SYSTEMS AND NOMOGRAMS 
         Prognostic systems and nomograms that combine independent 
prognostic factors have been recently developed. It has been suggested 
that these systems are more accurate than TNM stage or Fuhrman grade 
alone for predicting survival. In patients with RCC, TNM stage, nuclear 
grade according to Fuhrman and RCC subtype (WHO 2004) should be 
performed because they contribute important prognostic information.  
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There are currently no prognostic integrated systems or molecular 
markers recommended for routine clinical use. Several  groups have 
constructed prognostic  algorithms to facilitate clinical followup and 
identify patients for  adjuvant treatment.  
In 2001 the group at MSKCC proposed a nomogram for patients 
with localized clear cell, papillary and chromophobe RCC (63). 
Prognostic factors include tumor stage, tumor size, histological sub type 
and symptoms at presentation. A recently revised nomogram for patients 
with clear cell carcinoma from MSKCC   includes tumor stage, tumor 
size, nuclear grade, necrosis, vascular invasion and symptoms at 
presentation as prognostic factors. Paper nomograms gives a visual aid to 
clinicians to use during patient counseling. The software based 
nomograms provide accurate prognostic information and may take even 
less time to use during doctor patient interactions.Researchers at other 
institution have proposed 2 additional post operative prognostic 
nomogram systems. 
The UCLA integrated staging system UISS divide patients into 5 
Groups shown to have difference in survival. Initially the UCLA group 
has evaluated many prognostic parameters including age gender race and 
smoking history, the UISS is based solely on tumor stage nuclear grade 
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and ECOG performance status. In a subsequent report the UISS was 
modified to identify patients with non-metastatic or metastatic disease at 
low intermediate or high risk of disease progression. This modified UISS 
has been validated in larger series of patients internally and externally. 
A drawback of the UISS is that it does not predict the probability 
of failure for an individual patient and instead place individuals into low 
intermediate and high risk group, making information provide less 
meaningful for treatment decision making.  Grouping heterogeneous 
patients in particular into a high risk group leads to placement of patients 
who will do poorly with some who may never experience a recurrence. In 
2002 the group at Mayo clinic devised the SSIGN (65).Several 
investigators have now combined various prognostic factors, and this has 
greatly improved the predictive capacity (Cindolo et al, 2005). For 
instance, Kattan and colleagues (2001) have combined manner of 
presentation (incidental or local versus systemic symptoms), tumor 
histology, tumor size, and pathologic stage to develop a nomogram   that 
predicts cancer-free survival after nephrectomy.    
Tumor grade was not included in this analysis because its role for 
nonconventional RCC has not been clearly defined. A subsequent 
analysis from this same group focused only on patients with conventional 
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RCC and incorporated tumor grade, assessment of tumor necrosis, and 
vascular invasion to further improve prognostication (Sorbellini et al, 
2005). A similar model for conventional RCC has also been proposed by 
Frank and colleagues (2002) , in this case incorporating 1997 TNM stage, 
tumor size, nuclear grade, and presence of tumor necrosis to predict 
recurrence and survival after radical nephrectomy (Sengupta et al, 2005).  
A sophisticated multivariate analysis revealed three independent 
prognostic factors that were most robust for predicting outcomes, namely, 
TNM stage, performance status, and tumor grade ( Zisman et al, 2001b 
).Prediction of survival of patients has proved to be powerful, and this 
approach has now been validated in an independent analysis of 4202 
patients from eight academic centers  (Patardetal, 2004c ). Subsequent 
reports segregated patients with N0 M0 tumors from those with N+ or M1 
tumors and provided separate analyses for each subgroup, and this should 
be even more useful for the practicing clinician ( Zisman et al, 2002c ).  
Molecular factors such as staining for CA-9 and p53 and 
assessment of proliferation status with Ki-67 are now also being 
incorporated into algorithms to predict outcomes for patients with RCC 
(Kim et al, 2005).  
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For patients with clinically localized disease, Patard and colleagues 
(2004a) have shown that mode of presentation (incidental versus 
symptomatic) can be combined with tumor size to better stratify patients 
after primary surgical management. 
They have proposed a novel staging system for organ-confined RCC:  
T1a     <4.0 cm and incidental  T1b:    <4.0 cm and symptomatic or 
>4.0 cm and incidental   T2a:    >4 to ≤7 cm and symptomatic   T2b:    >7 
cm and symptomatic Cancer-specific mortality rates at 5 years of follow-
up were 1.9%, 4.1%, 13.8%, and 23.7%, respectively, showing that this 
simple modification could potentially improve prognostication for this 
population of patients ( Patard et al, 2004a ). Improved prognostication 
such as this will help guide counseling and management of patients and is 
likely to stimulate a reassessment of the current staging protocols for 
RCC.Prognostic systems or nomograms can be useful for the stratified 
inclusion of patients into clinical trials   
The use of integrated prognostic systems or nomograms is not 
routinely recommended, although these systems provide a rationale for a 
prognostic prediction useful for including patients in clinical trials. No 
molecular prognostic marker is currently recommended for utilization in 
the clinical routine. 
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MATERIALS AND METHODS 
Between September 2005 and December 2007, 85 patients  aged  
43- 74years  (mean 60yrs)  referred as  renal mass by incidental detection 
on evaluation of other diseases  or clinically presenting as loin pain, 
haematuria or renal mass were further evaluated    for RCC  by CECT 
KUB.  Any enhancing mass lesion in kidney was taken as renal cell 
carcinoma. All the patients were analysed regarding the presence or 
absence of symptoms such as mass, and paraneoplastic symptoms. 
           Laboratory investigations were done to detect the presence of 
paraneoplastic syndromes. Metastatic work included Doppler evaluation 
of renal veins and IVC and in selected cases MRI. Chest x-ray to rule out 
pulmonary metastasis and in selected  cases  chest CT done. Bone scan 
was done in cases presenting with bone pain or LFT showing raised 
alkaline phosphatase. CT brain was taken when patient’s symptoms 
suggested brain metastasis.   After confirming it is localized tumor 
without metastasis and with normal contralateral functioning kidney, 
radical nephrectomy was done.  In patients with IVC thrombus IVC 
thrombectomy was done.12 cases had metastasis at presentation.  
Remaining 73 cases were either localized or locally advanced and non 
metastatic  were managed by radical    nephrectomy  and proven by 
 42
histopathological  examination as renal cell carcinoma were enrolled in a    
prospective observational study. 6 cases were of benign histology and 
were excluded from study.   
  All the specimens were subjected to histopathological examination 
by institute pathologist .All factors the size, pathological stage, sub type, 
capsular invasion, sinus invasion, microvascular invasion, venous 
thrombus, venous invasion, margin status and nodal status were looked 
for. Specimen was specifically looked for tumor cells within the vascular 
system, which denotes microvascular invasion.   
FOLLOWUP- All patients were followed up with physical examination, 
serum chemistry, X -ray chest and CECT. This was done every 4 months 
in the 1st year, every 6 months in the 2nd year and annually thereafter. 
Univariate and Multivariate analyses were used to evaluate whether MVI 
was associated with disease free and cancer specific survival. Chi-square 
test was used to evaluate the association among the variables. Kaplan-
Meier method was used to develop survival curves. Differences among 
them were analysed using log –rank test. Cox-regression analysis was 
used to identify the factor which independently determines the recurrence 
and progression to death. A p value of < 0.05 was taken as significant. 
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EXCLUSION CRITERIA 
¾ Patients with metastatic disease at presentation 
¾ Patients in whom radical nephrectomy is not done due to 
associated comorbid conditions  
¾ Patients with CRF who develop RCC from Acquired Cystic 
Kidney Disease  
¾ Patients who have undergone partial nephrectomy 
¾ Patients with benign histopathological features 
¾ Patients with bilateral tumors at presentation 
¾ Patients with recurrence following partial nephrectomy 
¾ Patients with inconclusive malignant histology 
¾ Patients who developed post op medical complications and expired 
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RESULTS AND OBSERVATIONS 
Patient Demographics  
In our study there were totally  85 cases of  renal mass who were 
evaluated of which 12 cases presenting with metastasis were excluded 
from the study. Of the remaining cases the final histology was benign in 
6cases.On excluding these 6 cases only 67 cases were taken for the 
prospective observational study.     
 
 
                                                                
  
 
Of the 67 patients 55 (82%) were males   and 12 (18%) were 
females; the mean age was 60.3 yrs[43-74yrs] and the  mean follow up   
was  21 [6-36 ] months. In our study the tumors were common in males 
when compared to females. The commonest age of presentation was 6th 
and 7th decade. 
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Clinical Presentation 
At clinical presentation the tumor was incidental in 22(33%) and 
symptomatic in 45 (67%) with haematuria as the main presentation in 
31% of patients, mass in 24% of patients, both the findings in 35% and 
the classical triad in 10% of patients. The performance status was good in 
all the cases.There was no paraneoplastic  maniefestation. 
31%
24%
35%
10%
TRIAD
HAEMATURIA
MASS
MASS & HAEMATURIA
CLINICAL PRESENTATION
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Tumor Size 
In our study majority of tumors were more than 7 cms in size. 
Tumors  less than 4cms were around 22% in incidence. Presentation as 
mass and loin pain was more common in tumors more than 7cms size. 
Less  than 4 cm size was usually asymptomatic in presentation. 
 
 
 
 
 
 
Histological Subtype 
The distribution of histo pathological sub type was 90% clear cell 
carcinoma  and those who had MVI  all  developed recurrence. In 
papillary tumors MVI was detected in one case that developed 
recurrence. We had one case of bellini duct carcinoma in our study.    
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Pathological Stage 
 In our study 88% of cases were organ confined and 12% were 
locally advanced. They had adrenal invasion or capsular invasion by 
HPE. 
88%
22%
ORGAN CONFINED
PATHOLOGICAL STAGE
 
  The commonest pathological stage was T2 and the incidence of 
tumor with stage T1a was around 14%.only 7% incidence of T3a tumors. 
These T2 tumors had higher incidence of MVI 
.  
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Lymph Node Status And Necrosis 
Out of 8 positive lymph node cases 7 cases were MVI positive 
(p<.0001). Necrosis was present in 8% of our cases.  The incidence was 
more in higher grade tumors. 
        
 
 
 
MVI Incidence  
There was MVI in 13 (19%)   cases of whom 12 (92%) developed 
recurrence. The incidence of MVI was more in symptomatic tumors and 
the recurrence was more in symptomatic tumors with MVI. Incidental 
tumors with MVI also developed higher recurrence pattern in our cases. 
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Recurrence  
There was recurrence in 12 patients on follow up of whom 3 died 
from disease and 9 remained alive with disease.Only one patient 
developed local recurrence and all others developed systemic recurrence 
in lungs, bone and liver. One patient developed both local and systemic 
recurrence.Local recurrence was managed with resection and systemic 
recurrence by immunotherapy 
 
 
 
 
 
a)  Recurrence in Symptomatic Patients 
   MVI occurred in 3 cases (14%) of incidentally detected tumors and 
in 10 cases (23%) of symptomatic tumors (p value < 0.001) .There was a 
significant increase in tumor recurrence for symptomatic tumors. In  
both the clinical presentations MVI  was associated with recurrence  
(p value=0.008 for asymptomatic and <0.0001 for symptomatic patients). 
RECURRENCE RECURRENCE PATTERN 
0
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20
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 50
b)  Recurrence in Relation to Tumour Size 
Possible association  between  tumor size and MVI was analysed 
.In 10 tumors of < 4 cm size there was MVI in 1 case In 28 tumors of  4-7 
cm there was MVI in 1 tumor.In 39 tumors of more than 7 cm size 12 had 
MVI with p value of < 0.001. Those who had MVI had higher recurrence.   
 
 
 
 
c)  Recurrence and Tumour Grade 
There was MVI in 9%(5/55) of the low grade tumors but 
75%(9/12) of the high grade  tumors had MVI (P<.000I). All high grade 
tumours with MVI had recurrence where as low grade tumours 66% had 
recurrence if MVI was present. 
 
 
 
 
10
28
39
11 MVI
P < 0.001
1 MVI
1 MVI
< 4 CM
4 - 7CM
> 7CM
ASSOCIATION BETWEEN TUMOR SIZE & MVI
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d)  Recurrence and Tumour  Stage 
  For pathological stage there was MVI in only 5% of patients with 
stage I. Pathological stage III and stage IV had an incidence of 100% with 
p value < .0001. 
 
Further stratification of patients with stage 1 and 2 revealed that 
among those stage 1 no recurrence occurred for those without MVI .  
 
 
 
But the recurrence rate was about 50% for those with MVI  
(p<. 0001). In Stage 2 patients the recurrence rate was  100 % for with 
MVI. All Stage 3 and Stage4 patients with MVI had recurrences. 
Significance of MVI alone as a factor for recurrence is not available for 
analysis in high stage tumors  
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Survival Statistics 
In our study we analysed the disease free survival and the cancer 
specific survival There was recurrence in 12 cases of which 3 died of the 
disease and the remaining  cases were alive with the disease at the 
conclusion of the study. 
 
 
 
 
By looking at disease free survival curves the probability of disease 
free survival of all pts at 36 months was 74% over all. The disease free 
survival is affected by the recurrence of the disease.The probability of 
cancer specific survival was found to be 71 % for all patients in our 
study.   
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We also analysed  the how the cancer specific survival and disease 
free survival was affected by the presence of microvascular invasion. By 
looking at disease free survival curves the probability of disease free 
survival of all pts at 36 months was 26% with MVI and it was 85% 
without MVI. 
 
 
 
 
The probability of cancer specific survival was 35% with MVI  and 
86% without MVI. Cox regression analysis was used to compare the 
more important histological factor which revealed MVI was the most 
important prognostic factor.  
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DISCUSSION 
Factors influencing the recurrence following radical nephrectomy 
in organ confined or locally advanced RCC are anatomical, histological, 
clinical and molecular.Clinical factors include patient performance status, 
localized symptoms, cachexia, anaemia, platelet count Anemia, 
thrombocytosis, hypercalcemia, albuminuria, elevated serum alkaline 
phosphatase  erythrocyte sedimentation rate, and other para neoplastic 
signs or symptoms have also correlated with poor outcomes for patients 
with RCC 
The aim of our study was to find out the significance of established 
prognostic variables determining the recurrence and the significance of 
micro vascular invasion .In our study the incidence of tumors was about 
three times more common in males correlating with literature incidence. 
The recurrence was not altered by the sex status which implies biological 
behaviour of the tumor is same in both the sexes.      
In our study all patients had performance status of 0 or 1.There was 
no correlation between performance status and recurrence.  Patients with 
good performance status withstood the radical procedure well. But the 
performance status at recurrence determined the treatment because 
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immuno therapy was indicated in patient with good performance status 
only.  
Majority of our patients were in the age group of 60-70 yrs.  Age as 
a factor has been found to be significant in many studies revealing 
younger age group   has   favourable  prognosis and good out come. Age 
was not found to be a significant factor determining the recurrence in our 
study  
The lab variables were analysed which revealed that except in few 
cases of anaemia  no significant alteration in serum chemistry was seen. 
We did not find out any significance of these parameters. The incidence 
of paraneoplastic syndromes according to literature was 40%. But in our 
study non metastatic tumors did not have paraneoplastic syndromes but 
was found in metastatic tumors. The significance was not analysed 
because of non occurrence of paraneoplastic syndromes. 
The  incidental tumors were 22 and symptomatic tumors were 55 in 
our study.Symptomatic presentation  was associated with greater tumour 
size and higher grade and higher incidence of MVI.Those patients with 
symptomatic presentation and MVI had higher recurrence rate when 
compared to those without MVI and incidental with or without MVI. The 
size  of the  tumors varied  in our study with majority were more than 7 
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cm in size.  Taking   size into consideration  tumor recurrence occurred  
in  tumours more than 7 cm . Even in small tumors when they  had MVI 
they had recurrence.  So for varied tumor sizes  the presence of 
microvascular invasion was found to be statistically significant factor. 
      Most of the tumours were  pT2  and the grade was G2.In our study 
higher incidence of MVI was found in higher pathological stage.  All T3 
tumours had microvascular invasion and all G3 tumours had MVI.All the 
patients in this category developed recurrence.In pT1 tumours there was 
50% recurrence for tumours  with MVI.In pT2 tumours all patients 
developed recurrence if they had MVI. 
       The analysis of histological sub type revealed the clear cell was 
the commonest sub type and all the recurrences occurred in that except 
one case of Bellini duct carcinoma which developed recurrence. As per 
the literature chromophobe and  papillary tumors were found to be  of 
good prognosis . Since the number of cases of other histology was low in 
our study the statistical significance was not analysable There was one 
case of sarcomatoid histology which developed recurrence. 
The incidence of lymph node involvement was   in eight cases of 
which seven cases were microvascular invasion positive. The significance 
of lymph node positivity is these tumors had high recurrence and the 
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recurrence was due to higher pathological stage, higher grade and 
microvascular invasion present in these tumors. The significance of MVI 
in these cases is not known as they had high chance of recurrence even in 
the absence of microvascular invasion.                   
The incidence of necrosis varied in our cases and the statistical 
analysis did not reveal any significance. The presence of venous thrombi 
occurred in two cases which were managed by thrombectomy.There was 
no case of venous wall invasion which required venacavectomy.  
Recurrence was not altered by presence of venous thrombi in our study.                     
Adrenal invasion was seen in three cases which were by direct 
contiguous spread there was no statistical significance for this finding in 
our study. All the cases adrenalectomy was performed except in few 
cases which had a small tumor in lower pole and adrenal was normal by 
pre operative evaluation and intraoperatively. 
 So we analysed in our study the individual prognostic factors that 
influenced the recurrence and how the MVI increased the recurrence by 
combining with these factors and how much it increased the risk over 
these factors alone. Our study revealed  for the size, pathological stage, 
grade the presence of MVI increased their influence on recurrence over 
their individual contribution 
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Recurrence was seen in 12 cases with 2 local recurrence and 10 as 
systemic recurrence. Out of the 12 cases 10 had MVI (83%). 
Haematogenous malignant dissemination relies on tumor access to 
microvasculature which alone confers on these tumors a higher risk of 
developing metastasis (van poppel etal) reported a 39% percentage rate 
of disease progression tumors with MVI and 6% without MVI. 
In other study, Dekel etal  reported similar findings ,with  disease 
progression rates of  55.5 percentage for patients with MVI . The present  
results  clearly shows  that MVI  is an important independent risk factor  
disease free survival [85 vs 26 ]   and cancer specific survival  [86 vs  35]  
for negative and positive MVI respectively. 
Mrstik et al reported disease progression rate of 55.5% for pts 
with MVI. A study by Marcos etal  in 230 patients  revealed MVI  in  59 
patients  of these  46 percentage developed recurrence . Among the 171 
patients with no MVI only 11 developed recurrence. An association 
between MVI and the tumor size suggests its relationship with volumetric 
tumor growth. Even for patients  with tumors less than 4cm  and of low 
grade  the presence of MVI  should mandate  a close follow-up  as  one  
patient has developed recurrence. 
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The incidence of MVI increased with pathological stage even in 
patients with stage 1and 2 incidence of MVI influenced the recurrence. 
So this finding should  always be reported   by pathologists  and must be  
strongly considered  when following   up regimen of these  patients .Our 
study showed  that the presence of MVI  in patients with RCC  
undergoing  surgery  suggests  a more aggressive followup . This   
finding if validated by further studies might determine the use of adjuvant 
therapy 
     In our study the probability of cancer specific survival was 71 % 
for all patients  with MVI it was 35% and without MVI it was 86%.The 
median survival  at  3 yrs for patients  whose  tumor had  no MVI was  95 
percentage and statistically better than that of patients  whose tumors  had 
MVI[25  percentage] with a relative risk of death of 4.23. This was the 
most significant independent factor when compared with established 
clinical and histopathological variables. 
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CONCLUSION 
We have found the significant variables for recurrence are size of 
tumor more than 7cm, pathological stage, lymph node positivity,tumor 
grade and microvascular  invasion. Of all the variables micro vascular 
invasion proved to be the most important factor determining the 
recurrence. Patients with MVI should be closely followed or might be 
considered for trials of adjuvant therapy. 
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PATIENT PROFORMA 
 
1. NAME:  
 
2. SERIAL NUMBER: 
 
3. AGE:      
 
4. SEX:                                                                             
 
5. CLINICAL PRESENTATION:       
                                                        INCIDENTAL 
                                                        LOCAL/SYSTEMIC  SYMPTOMS 
 
 
6. LAB VARIABLES:                     
                                                      ANAEMIA 
                                                     SR CALCIUM 
                                                      ESR 
                                                      LFT 
 
 7.INVESTIGATIONS:        X-RAY CHEST, USG,CT/MRI , 
BONE SCAN 
 
 
 8.SURGICAL PROCEDURE: 
 
 9.HISTOPATHOLOGICAL ASSESSMENT: 
 
TUMOR SIZE 
                                                            HISTOPATHOLOGICAL SUB TYPE 
                                                           PATHOLOGICAL STAGE 
                                                            MICROVASCULAR INVASION 
                                                           NODAL STATUS 
                                                          MARGIN  STATUS 
10.POST OP FOLLOW UP: 
 
                                                      PHYSICAL EXAMINATION 
                                                           LFT 
                                                        X/RAY CHEST 
                                                USG/CT SCAN  
                       
                                                   EVERY 4MONTHS FOR  1ST  YEAR 
 
                                                            EVERY 6 MONTHS FOR 2ND  YEAR  
  
                                                         EVERY 12 MONTHSFROM 3RD YEAR 
 11.FOLLOW UP RESULT 
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MASTER CHART 
 
S.NO AGE SEX SYMP 
SIZE  
(cm ) HPE GRA NEC 
     
MVI NOD STAGE ECOG REC 
1 47 M I 5 CRCC 1 A P A T1B 0 Y 
2 62 M L 10 CRCC 2 A A A T2 1  - 
3 72 F L 8 CRCC 2 A A A T1B 1       - 
4 62 M I 3 CRCC 1 A A A T1A 1        - 
5 59 M I 7 CRCC 2 A A A T1B 0 - 
6 48 M I 4 CRCC 1 A P A T1A 0  - 
7 61 M L 8 CRCC 1 A A A T2 0 - 
8 59 F I 6 
PAP 
RCC 1 A A A T1B 1  - 
9 60 M I 4 CRCC 1 A A A T1A 1  - 
10 43 F L 16 CRCC 3 P P P T3A 1 Y 
11 66 M L 14 CRCC 3 P P P T3A 1 Y 
12 72 M L 10 CRCC 3 P P P T3A 1 Y 
13 64 M L 5 
PAP 
RCC 1 A A A T1B 1  - 
14 48 M I 5 CRCC 1 A A A T1B 1  - 
15 49 F L 10 CRCC 2 A A A T2 0  - 
16 63 M I 5 
CHR 
RCC 1 A A A T1B 0  - 
17 57 M L 18 CRCC 3 A P P T3A 0 Y 
18 73 M I 5 CRCC 1 A A A T1B 1  - 
19 64 M L 20 CRCC 3 A P P T3A 1 Y 
20 65 F L 6 CRCC 1 A A A T1B 1  - 
21 69 M I 5 CRCC 1 A A A T1B 1 - 
22 60 M I 2 CRCC 1 A A A T1A 0       - 
23 57 M L 5 CRCC 1 A A A T1B 0  - 
24 64 M I 8 CRCC 2 A P A T2 0 Y 
25 46 M I 3 
PAP 
RCC 1 A A A T1A 1  - 
26 49 F L 8 CRCC 2 A A A T2 1  - 
27 55 M L 8 CRCC 2 A A A T2 1  - 
28 50 M L 9 CRCC 2 A A A T2 1  - 
29 56 M L 6 CRCC 2 A A A T1B 0  - 
30 68 M I 3 CRCC 1 A A A T1A 1  - 
31 64 M L 10 CRCC 2 A A P T3A 0 Y 
32 63 F L 8 CRCC 2 A A A T2 1  - 
33 59 M L 5 CRCC 1 A A A T1B 1  - 
34 59 M L 7 CRCC 1 A A A T1B 1  - 
35 62 F L 8 CRCC 1 A A A T2 0 - 
36 72 M L 8 CRCC 1 A A A T2 1  - 
37 73 M L 8 CRCC 1 A P A T2 0 - 
38 60 M L 5 CRCC 1 A A A T1B 0 - 
39 61 F I 3 CRCC 1 A A A T1A 1       - 
40 58 M I 2 CRCC 1 A A A T1A 0 - 
41 49 M I 4 CRCC 1 A A A T1A 1 - 
42 56 M L 9 
PAP 
RCC 2 A A A T2 0 - 
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43 46 M L 10 CRCC 3 A A A T2 1 - 
44 73 M L 7 CRCC 2 A A A T1B 0 - 
45 62 M L 8 CRCC 2 A A A T2 0 - 
46 63 M L 12 CRCC 3 A P A T2 1 Y 
47 66 M L 8 CRCC 1 A A A T2 1  - 
48 58 M L 8 
PAP 
RCC 2 A A A T2 1  - 
49 53 M I 3 CRCC 1 A A A T1A 1  - 
50 54 F L 7 CRCC 2 A A A T1B 1 - 
51 55 F L 8 CRCC 3 A A A T2 1 Y 
52 60 M L 16 BELLINI 3 A P P T3A 0 Y 
53 62 M L 9 CRCC 2 A A A T2 1  - 
54 63 F L 9 CRCC 2 A A A T2 1  - 
55 64 M L 10 CRCC 2 A A A T2 1  - 
56 53 M L 11 
CHR 
RCC 2 A P A T2 1 - 
57 54 M L 8 CRCC 2 A A A T2 1  - 
58 49 M I 8 CRCC 2 A A A T2 1  - 
59 50 M L 14 CRCC 3 P P P T3A 0 Y 
60 72 M L 10 CRCC 3 A A A T2 1  - 
61 73 M I 8 CRCC 2 A A A T2 1  - 
62 74 M L 10 CRCC 3 A A A T2 1  - 
63 70 M L 8 CRCC 2 A A A T2 1  - 
64 68 M L 8 CRCC 2 A A A T2 0  - 
65 66 M I 7 CRCC 2 A A A T1B 1  - 
66 64 M L 8 CRCC 2 A A A T2 1  - 
67 68 M I 7 
PAP 
RCC 2 A A A T1B 1  - 
 
ABBREVIATIONS 
 
M-MALE 
F- FEMALE 
L – LOCAL SYMPTOMS 
I – INCIDENTAL 
CRCC – CLEAR CELL RENAL CELL CANCER 
PAP RCC – PAPILLARY RCC 
REC-RECURRENCE 
MVI-MICROVASCULAR INVASION 
GRD-GRADE 
NEC-NECROSIS 
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